2024 Immune Response Molecular Biology Pharma Companies 
Drug Discovery World
MAY 6, 2024
In an example of venture capital in the city, another AI-driven biotech Aqemia raised €30 million in January 2024 in an extension to its Series A financing, bringing total funding for the round to an impressive €60 million. So, in this way there is a cross fertilisation from the bigger companies to newer ones.
Codon
FEBRUARY 13, 2024
Such contaminants could have the same toxic effects as the bacterial infection, or provoke a severe immune response in the patient, and therefore the phage mixtures must go through extensive purification and testing procedures. Asimov Press (2024). Cite this essay: Tom Ireland. Scaling Phage Therapy."
Expert insights. Personalized for you.
147 
Let's personalize your content